Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,307.60 -0.53 (-0.01%) Dow
39,860.87 +54.10 (+0.14%) Nasdaq
16,759.99 -34.88 (-0.21%) Bitcoin USD
70,711.83 +3,651.66 (+5.45%) CMC Crypto 200
1,530.39 +41.85 (+2.81%)
UCB SA (UCB.BR)
| Previous close | 126.70 |
| Open | 126.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 124.80 - 126.95 |
| 52-week range | 65.40 - 126.95 |
| Volume | |
| Avg. volume | 314,095 |
| Market cap | 24.054B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 72.02 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.36 (1.07%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
- PR Newswire
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
- PR Newswire
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
